



## **Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6,  
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,  
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000,

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

May 20, 2026

To,

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Scrip code: 512529**

**Scrip code: VIYASH**

Dear Sir/ Madam,

**Subject: Extract of Audited Financial Results – Copy of Newspaper Advertisement**

Pursuant to the provision of Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on May 20, 2026, in The Financial Express (English) and Nava Telangana (Telegu) newspapers providing Extracts of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

For **Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

**Yoshita Vora**

**Company Secretary & Compliance Officer**

**NOTICE**  
 Notice is hereby given that the 28<sup>th</sup> Annual General Meeting ('AGM') of the Members of the Company is scheduled to be held on Thursday, August 06, 2026 at 03.30 P.M. (IST) through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'), to transact the business items as mentioned in the AGM Notice, in compliance with the applicable provisions of the Companies Act, 2013 read with the rules made thereunder ('the Act') and General Circular of Ministry of Corporate Affairs ('MCA') dated September 22, 2025 along with other applicable Circulars (collectively referred as 'MCA Circulars'), without the physical presence of the Members at a common venue. Members attending the AGM through VC / OAVM will be considered for quorum under Section 103 of the Act.

The Annual Report of the Company for the financial year 2025-2026, including the AGM Notice and e-voting instructions, will be sent electronically to all Members whose e-mail IDs are registered with the Company / the Company's Registrar and Share Transfer Agent viz. KFin Technologies Limited ('KFinTech') / respective Depository Participant ('DP') unless any Member has requested for a physical copy. The same will also be made available on the website of the Company at [https://www.nfil.in/investor/annu\\_reports.html](https://www.nfil.in/investor/annu_reports.html), BSE Limited at [www.bseindia.com](http://www.bseindia.com), National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) and National Securities Depository Limited at [www.evoting.nsdl.com](http://www.evoting.nsdl.com). A letter providing web-link for accessing the Annual Report will be sent to those Members who have not registered their e-mail ID.

To receive the Annual Report including Notice of AGM and e-voting instructions electronically, Members who have not registered their e-mail IDs may note the following for registering the same:

- Members holding equity shares in demat form may register their e-mail IDs with their respective DP.
- Members holding equity shares in physical form may fill Form ISR 1 which, along with other relevant details, which is available at <https://www.nfil.in/investor/downloads.html> and <https://ris.kfintech.com/clientservices/investors/isrs.aspx> and send the same to KFinTech through such modes as specified in the Form. The correspondence details of KFinTech are: KFin Technologies Limited, Unit: Navin Fluorine International Limited, Selenium Building, Tower-B, Plot No. 31 & 32, Financial District, Hyderabad 500032, India; Tel.: +91 40 6716 2222 / 40 2342 0814 / 1800 3094 001; E-mail ID: einward.ris@kfintech.com; Website: [www.kfintech.com](http://www.kfintech.com)

Members holding equity shares as on the Cut-Off Date will have an opportunity to cast their votes electronically on the Business Items set forth in the AGM Notice, either through remote e-voting or e-voting at the AGM. In this regard, the detailed procedure for Members who hold equity shares in demat form, physical form and Members whose e-mail IDs are not registered will be provided in the AGM Notice to enable them to cast their votes.

The final dividend of ₹8.60 per equity share of ₹2/- each, as recommended by the Board of Directors of the Company for the financial year ended March 31, 2026, if declared at the ensuing AGM, will be paid to the eligible Members on or after August 13, 2026. As per Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Friday, June 12, 2026 is fixed as the Record Date for ascertaining eligibility of Members for the said final dividend. The dividend will be paid by only electronic mode to Members who have registered/updated their bank account details with the Company/KFinTech/DPs. Payment of dividend through demand drafts or dividend warrants has been discontinued.

Pursuant to relevant SEBI Circulars, with effect from April 01, 2024, dividend shall be paid only through electronic mode to members holding shares in physical form only if the folio is KYC compliant by updation of documents / details such as furnishing of contact details, bank account details, specimen signature, in the forms as prescribed by SEBI and valid PAN linked to Aadhaar as may be applicable. In case physical folios are not updated with KYC details, with effect from April 01, 2024, the dividend shall be withheld and released only upon the updation of KYC.

In order to receive direct credit of dividend amount in the bank account:

- Members holding equity shares in demat form are requested to update their bank account details with their respective DP;
- Members holding equity shares in physical form are requested to submit a covering letter, duly signed Form ISR 1 available at the web-link at <https://www.nfil.in/investor/downloads.html> and <https://ris.kfintech.com/clientservices/investors/isrs.aspx> along with documents mentioned therein through such modes as specified in the Form. The correspondence details of KFinTech are mentioned above.

Dividend income is taxable in the hands of Members w.e.f. April 01, 2020 and the Company is required to deduct tax at source from dividend paid to Members at the prescribed rates as applicable. In this regard, Members are requested to submit relevant documents to the Company as per the detailed communication which has been sent by the Company to Members who have registered their e-mail IDs. The same is also available on the Company's website at [https://nfil.in/investor/comp\\_announce.html](https://nfil.in/investor/comp_announce.html) and the website of the Stock Exchanges.

TDS certificates regarding dividends declared in the past can be downloaded from <https://ris.kfintech.com/clientservices/tlds/>

By order of the Board of Directors  
**For Navin Fluorine International Limited**  
 Sd/-  
**Niraj B. Mankad**  
 President Legal &  
 Company Secretary

Date: May 19, 2026  
 Place: Mumbai



**J. KUMAR INFRAPROJECTS LTD.**  
 CIN : L74210MH1999PLC122886  
 Reg. Office: J.Kumar House , CTS No. 448, 448/1, 449, Vile Parle (East), Subhash Road, Mumbai 400057, Maharashtra, India  
 Tel: 022-67743555, Fax 022-26730814, Email- info@jkumar.com, Website: www.jkumar.com

**EXTRACTS OF THE AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH 2026**

(₹ in Lakhs)

Particulars	STANDALONE				CONSOLIDATED			
	Quarter Ended	Quarter Ended	Year Ended	Year Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
	31-Mar-2026 Audited	31-Mar-2025 Audited	31-Mar-2026 Audited	31-Mar-2025 Audited	31-Mar-2026 Audited	31-Mar-2025 Audited	31-Mar-2026 Audited	31-Mar-2025 Audited
Total Income	1,60,376.34	1,64,262.09	5,76,878.26	5,72,648.87	1,61,653.73	1,64,262.09	5,80,110.81	5,72,648.87
Profit/(loss) before Share of profit/(loss) of associates/joint ventures, exceptional items and tax	14,411.37	15,735.42	53,728.73	53,548.15	14,679.79	15,735.42	53,780.47	53,548.15
Profit/(loss) before exceptional items and tax	14,411.37	15,735.42	53,728.73	53,548.15	14,740.45	15,741.21	53,912.35	53,623.98
Net Profit/ (Loss) for the period Before tax (After Exceptional and/or Extraordinary Items)	14,411.37	15,735.42	52,492.12	53,548.15	14,891.55	15,741.21	52,826.84	53,623.98
Profit after tax (6-7)	10,549.04	11,414.36	38,355.12	39,044.88	11,029.22	11,420.16	38,689.83	39,120.72
Total comprehensive income (8+9)	10,784.02	11,674.10	38,789.29	39,310.47	11,276.81	11,678.58	39,136.62	39,386.31
Equity Share Capital	3,783.28	3,783.28	3,783.28	3,783.28	3,783.28	3,783.28	3,783.28	3,783.28
Earning per Share (in ₹ ) Face Value of ₹ 5/- each								
(a) Basic	13.94	15.09	50.69	51.60	14.58	15.09	51.13	51.70
(a) Diluted	13.94	15.09	50.69	51.60	14.58	15.09	51.13	51.70

**Notes:**  
 1. The above is an extract of the detailed format of the Audited Financial Results for the quarter and year ended March 31, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results is available on the website of the Company at [www.jkumar.com](http://www.jkumar.com) and on the websites of the Stock Exchanges at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) respectively.  
 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on May 19, 2026. The same can be accessed by scanning the QR Code provided below.

By Order of the Board  
 For J. Kumar Infraprojects Limited  
**Jagdishkumar M. Gupta**  
 Executive Chairman

Date : May 19, 2026  
 Place : Mumbai

**Sun Pharmaceutical Industries Limited**  
 Regd. Office: SPARC, Tandajia, Vadodara - 390 012, Gujarat, India  
 Corporate Office: Sun House, Plot No. 201 8/1, Western Express Highway, Goregaon - East, Mumbai - 400 063, Maharashtra, India  
 Tel: 022-43244324 | CIN: L24200G1999PLC019050  
 Website: www.sunpharma.com | Email: secretarial@sunpharma.com

**Notice for Special Window for transfer of physical shares**

This is to inform you that SEBI vide circular no. HO/38/13/11(2)2026-MIRSD-POD/L/3750/2026 dated 30 January 2026, has decided to open another special window for a period of one year from 05 February 2026 to 04 February 2027, for transfer of physical shares, which were sold/purchased prior to 01 April 2019, including such transfer requests which were submitted earlier and were rejected or returned or not attended to due to deficiency in the documents/ process/or otherwise, in order to facilitate ease of investing for investors and to secure the rights of investors in the securities which were purchased by them. During this period, the securities so transferred shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred/lien-marked/pledged during the said lock-in period.

The concerned investors are once again requested to take advantage of this Special Window, which remains open until 04 February 2027, to submit the documents such as: (a) Original share certificate(s), (b) Transfer deed executed prior to 01 April 2019, (c) Proof of purchase by Transferee, as may be available, (d) KYC documents of the transferee (as per ISR forms), (e) Latest Client Master List (CML), not older than 2 months, of the demat account of the transferee, duly attested by Depository Participant, (f) Undertaking cum Indemnity, to our Registrar and Transfer Agent ('RTA'), whose address is below, within the above-mentioned period.

**MUFG Intime India Private Limited**  
 (Formerly Link Intime India Private Limited)  
 C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083, Maharashtra, India  
 Tel. No.: +91 810 811 6767  
 Email: investor.helpdesk@in.mfms.mufg.com  
 Portal: <https://swayam.in.mfms.mufg.com/>  
 Website: [https://web.in.mfms.mufg.com/helpdesk/Service\\_Request.html](https://web.in.mfms.mufg.com/helpdesk/Service_Request.html)  
 For more details, you may contact our RTA, MUFG Intime India Private Limited,  
**For Sun Pharmaceutical Industries Limited**  
 (Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
 ICSI Membership No. A23983

Place : Mumbai  
 Date : 19 May 2026

**AUTOMOBILE PRODUCTS OF INDIA LIMITED**  
 CIN: L34103MH1949PLC326977  
 Registered Office: Unit No.F-1, 1st Floor, Shanti Nagar Co-op Indl. Estate Ltd., Vakola, Santacruz (East), Mumbai - 400055.

**Extracts of Statement of Audited Financial Results for the Quarter and Year ended March 31, 2026**

(Rs. in Lacs)

Particulars	Quarter Ended		Year Ended	
	31-03-2026 (Audited)	31-12-2025 (Un-Audited)	31-03-2025 (Audited)	31-03-2026 (Audited)
	Total Income from operations	4.25	4.25	4.25
Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(24.07)	(58.48)	(68.53)	(172.90)
Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(24.07)	(58.48)	(68.53)	(172.90)
Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(23.69)	(57.85)	(68.34)	(173.42)
Total Comprehensive Income for the period (comprising profit or loss) for the period after tax and other Comprehensive income after tax	(25.19)	(57.85)	(68.07)	(174.92)
Equity Share Capital	48.18	48.18	48.18	48.18
Reserves excluding revaluation reserve as per audited balance sheet of previous accounting year	-	-	-	(1,614.93)
Earnings Per Share (of Rs. 1/- each)-Basic & diluted (not annualised)	(0.49)	(1.20)	(1.42)	(3.60)

The above is an extract of the detailed format of Audited Financial Results for the Quarter and Year ended March 31, 2026 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results for the Quarter and Year ended March 31, 2026 are available on the BSE website at [www.bseindia.com](http://www.bseindia.com) and on the company's website [www.apimumbai.com](http://www.apimumbai.com). & can be accessed by scanning the given quick response code.

By order of the Board  
**Shyam Agarwal**  
 Director  
 (DIN 00039991)

Place : Mumbai  
 Date : 19.05.2026

**PRINCE PIPING SYSTEMS**

**PRINCE PIPES AND FITTINGS LIMITED**

Regd Off: Survey No. 132/1/13, Athal road, Village Athal, Naroli, Silvassa, Dadra Nagar Haveli - 396235  
 Corp Off: 8th Floor, The Ruby, 29, Senapati Bapat Marg, (Tulsi Pipe Road), Dadar West, Mumbai 400028  
 Tel No.: 022-6602 2222 | Fax No.: 022 6602 2220  
 Email id.: investor@princepipes.com | Website: www.Princepipes.com  
 CIN: L26932DN1987PLC005837

**EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED AND AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026**

Rs in million

Sr. No.	Particulars	Three months ended 31.03.2026 (Unaudited)	Three months ended 31.12.2025 (Unaudited)	Three months ended 31.03.2025 (Audited)	Year Ended 31.03.2026 (Audited)	Year Ended 31.03.2025 (Audited)
1.	Revenue from Operations	8,500.73	5,732.70	7,196.54	25,983.32	25,239.16
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	756.21	0.38	299.36	1,017.84	588.47
3.	Net Profit / (Loss) for the period after tax (before Exceptional and/or Extraordinary items)	561.05	(3.28)	241.78	752.30	431.35
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	561.05	(23.77)	241.78	731.82	431.35
5.	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	559.15	(18.79)	243.30	735.93	430.93
6.	Equity Share Capital (Face value of Rs 10/- each)	1,105.61	1,105.61	1,105.61	1,105.61	1,105.61
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited balance sheet of the previous year				15,339.47	14,658.79
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -					
	1. Basic (excluding exceptional item)	5.07	(0.03)	2.19	6.80	3.90
	2. Basic (including exceptional item)	5.07	(0.21)	2.19	6.62	3.90
	3. Diluted (excluding exceptional item)	5.07	(0.03)	2.19	6.80	3.90
	4. Diluted(including exceptional item)	5.07	(0.21)	2.19	6.62	3.90

**Notes:**  
 1. The above is an extract of the detailed format of the standalone for the quarter and financial year ended 31st March 2026, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Financial Results for the quarter and financial year ended 31st March 2026 is available on the Stock Exchange website [www.bseindia.com](http://www.bseindia.com), [www.nseindia.com](http://www.nseindia.com) and Company's website [www.princepipes.com](http://www.princepipes.com).  
 2. The above results were reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 19.05.2026 and have been audited by the Statutory Auditors of the Company.  
 3. Figures for the quarter ended 31.03.2026 and 31.03.2025 represents the difference between the audited figures in respect to the full financial year and published figures of period ended 31.12.2025 (limited reviewed) and 31.12.2024 (limited reviewed).  
 4. The Board of Directors of the Company at its meeting held on 19.05.2026 have recommended a final dividend of Re. 1 per share of face value of Rs. 10/- each for the year ended 31.03.2026 which is subject to shareholders approval in ensuing annual general meeting.  
 5. Effective November 21, 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four labour codes collectively referred to as "The New Labour Code". This has resulted in estimated increase in provision for employee benefits of the Company amounting to Rs 20.48 million (net of tax) presented under Exceptional Items for the quarter ended 31.12.2025 and year ended 31.03.2026. The Company will re-evaluate the impact of these Labour Codes upon notification of the rules, corresponding State level regulations and further clarification/guidance in the matter and impact whereof, if any, will be recognised thereafter.  
 6. During the current year, as per para 6(e) of Ind AS 23 "Borrowing costs", the exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs are regrouped from other exchange differences to finance costs.  
 7. Finance cost for the quarter ended 31.12.2025 and year ended 31.03.2026 is net of interest subvention for the Bihar plant aggregating to INR 64.44 million.  
 8. Sales for the quarter ended 31.12.2025 and year ended 31.03.2026 includes write back of INR 51.50 million towards excess scheme provision for earlier period.  
 9. The Company is primarily engaged in manufacturing and selling of Pipes, Fittings and allied products in India. It comprises of Pipes and Fittings, Bathroom sanitary and Faucet and allied products.

For and on behalf of Board  
**Prince Pipes and Fittings Limited**  
 Sd/-  
**Jayant Shamji Chheda**  
 Chairman & Managing Director  
 (DIN: 00013206)

Date : May 19, 2026,  
 Place : Mumbai

**Viyash**

**VIYASH SCIENTIFIC LIMITED**  
 (Formerly known as Sequent Scientific Limited)  
 CIN: L99999TS1985PLC196357

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttaia Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.  
 E-mail: investorrelations@viyash.com, E-mail: info@viyash.com, Website: www.viyash.com Tel No.: +91 40 23635000

**EXTRACT OF THE AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026**

(₹ in Million)

Particulars	3 months ended 31-Mar-2026	Preceding 3 months ended 31-Dec-2025	Corresponding 3 months ended in previous period 31-Mar-2025	Current year ended 31-Mar-2026	Previous year ended 31-Mar-2025
	Audited	Unaudited	Audited (referred note 2)	Audited	Audited (referred note 2)
	Revenue from operations	9,199.60	8,584.10	7,723.10	34,203.10
Profit before tax and exceptional items	1,252.40	1,143.30	376.90	3,932.30	947.40
Profit / (loss) before tax and after exceptional items	1,252.40	730.70	(366.60)	3,490.20	131.80
Profit / (loss) after tax	663.80	485.20	(321.80)	2,246.50	157.70
Total comprehensive income, net of tax	1,054.00	514.30	464.30	3,315.50	308.00
Equity share capital	873.70	872.20	500.60	873.70	500.60
Other equity				28,236.90	23,815.30
<b>Earnings per equity share:(face value of ₹ 2 each) (not annualised)</b>					
Basic (in ₹ )	1.20	0.89	(0.61)	4.09	0.54
Diluted (in ₹ )	1.17	0.87	(0.61)	4.01	0.53

**SUMMARIZED AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026**

(₹ in Million)

Particulars	3 months ended 31-Mar-2026	Preceding 3 months ended 31-Dec-2025	Corresponding 3 months ended in previous period 31-Mar-2025	Current year ended 31-Mar-2026	Previous year ended 31-Mar-2025
	Audited	Unaudited	Audited (referred note 2)	Audited	Audited (referred note 2)
	Revenue from operations	3,724.90	3,416.40	3,443.20	13,820.60
Profit before tax and exceptional items	487.50	518.70	440.60	1,604.30	1,306.40
Profit / (loss) before tax and after exceptional items	487.50	106.10	(302.00)	1,162.20	491.70
Profit / (loss) after tax	358.10	(0.80)	(193.70)	758.70	584.90
Total comprehensive income / (loss), net of tax	350.10	(3.30)	(210.20)	748.90	581.70

**Notes:**  
 1. The above information has been extracted from the detailed financial results for the quarter and year ended 31 March 2026 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.  
 2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symbio Labs Limited, Vandana Life Sciences Private Limited, Appure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.  
 The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the year ended 31 March 2026. As per the terms of the Scheme, the Company has allotted 18,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925.20 million during the year ended 31 March 2026 (representing 25% of Warrant consideration as per the Scheme).  
 The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the consolidated financial results of the Group in respect of the corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.  
 3. The full format of the financial results for the quarter and year ended 31 March 2026 are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) & [www.nseindia.com](http://www.nseindia.com)) and Company's website ([www.viyash.com](http://www.viyash.com)).

For Viyash Scientific Limited  
 (Formerly known as Sequent Scientific Limited)  
**Dr. Hari Babu Bodepudi**  
 Managing Director and Group CEO  
 (DIN -01119687)

Place: Hyderabad  
 Date: 19 May 2026

